SAR341402
Total Payments
$3.7M
Transactions
1,486
Doctors
17
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1.8M | 465 | 17 |
| 2018 | $1.9M | 1,021 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.7M | 1,486 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period | SANOFI US SERVICES INC. | $2.3M | 1 |
| Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine | SANOFI US SERVICES INC. | $1.1M | 1 |
| Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 | SANOFI US SERVICES INC. | $291,727 | 2 |
| Safety Assessment of SAR341402 and NovoLog Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM) | SANOFI US SERVICES INC. | $48,561 | 0 |
| Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog? Versus Continuous Use of NovoLog in Participants With Type | SANOFI US SERVICES INC. | $17,631 | 15 |
| Eff- Solution- T1DM (US only)- Interchangeability study | SANOFI US SERVICES INC. | $6,236 | 0 |
| SAFETY ASSESSMENT OF SAR341402 AND NOVOLOG? USED IN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) IN ADULT PATIENTS WITH TYPE 1 DIABETES MELLITUS (T1DM) | SANOFI US SERVICES INC. | $545.61 | 0 |
Top Doctors Receiving Payments for SAR341402
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Research Triangle Park, NC | $3.6M | 1,313 |
| , M.D | Endocrinology, Diabetes & Metabolism | Rockville, MD | $102,246 | 15 |
| , MD | Specialist | Chattanooga, TN | $6,500 | 1 |
| , MD | Internal Medicine | Las Vegas, NV | $1,710 | 13 |
| , M.D | Internal Medicine | Concord, CA | $1,520 | 11 |
| , M.D | Plastic Surgery | Washington, MO | $1,340 | 11 |
| , MD | Internal Medicine | Aurora, CO | $1,235 | 11 |
| , M.D | Internal Medicine | Mesquite, TX | $1,209 | 11 |
| , M.D | Endocrinology, Diabetes & Metabolism | Ocoee, FL | $1,197 | 12 |
| , M.D | Endocrinology, Diabetes & Metabolism | Houston, TX | $1,181 | 14 |
| , M.D | Internal Medicine | Hamden, CT | $1,127 | 13 |
| , M.D., PHD | Endocrinology, Diabetes & Metabolism | Mchenry, IL | $1,106 | 10 |
| , M.D | Endocrinology, Diabetes & Metabolism | Roswell, GA | $1,084 | 7 |
| , MD | Family Medicine | New Port Richey, FL | $1,075 | 12 |
| , M.D | Internal Medicine | Palm Harbor, FL | $1,023 | 11 |
| , MD | Cardiovascular Disease | Doral, FL | $993.02 | 7 |
| , M.D | Endocrinology, Diabetes & Metabolism | Columbus, GA | $951.98 | 7 |
| , M.D | Endocrinology, Diabetes & Metabolism | Arlington Heights, IL | $878.40 | 7 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $3.7M
Product Information
- Type Drug
- Total Payments $3.7M
- Total Doctors 17
- Transactions 1,486
About SAR341402
SAR341402 is a drug associated with $3.7M in payments to 17 healthcare providers, recorded across 1,486 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2018 to 2019. In 2019, $1.8M was paid across 465 transactions to 17 doctors.
The most common payment nature for SAR341402 is "Unspecified" ($3.7M, 100.0% of total).
SAR341402 is associated with 7 research studies, including "Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period" ($2.3M).